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ARTICLE
Heterologous expression reveals the biosynthesis
of the antibiotic pleuromutilin and generates
bioactive semi-synthetic derivatives
Fabrizio Alberti 1,3, Khairunisa Khairudin1, Edith Rodriguez Venegas2, Jonathan A. Davies2, Patrick M. Hayes1,
Christine L. Willis2, Andy M. Bailey1 & Gary D. Foster 1
The rise in antibiotic resistance is a major threat for human health. Basidiomycete fungi
represent an untapped source of underexploited antimicrobials, with pleuromutilin—a
diterpene produced by Clitopilus passeckerianus—being the only antibiotic from these fungi
leading to commercial derivatives. Here we report genetic characterisation of the steps
involved in pleuromutilin biosynthesis, through rational heterologous expression in Aspergillus
oryzae coupled with isolation and detailed structural elucidation of the pathway intermediates
by spectroscopic methods and comparison with synthetic standards. A. oryzae was further
established as a platform for bio-conversion of chemically modiﬁed analogues of
pleuromutilin intermediates, and was employed to generate a semi-synthetic pleuromutilin
derivative with enhanced antibiotic activity. These studies pave the way for future char-
acterisation of biosynthetic pathways of other basidiomycete natural products in ascomycete
heterologous hosts, and open up new possibilities of further chemical modiﬁcation for the
growing class of potent pleuromutilin antibiotics.
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P leuromutilin is a diterpene natural product with anti-microbial properties, whose tricyclic skeleton has served asa precursor for semi-synthetic derivatives used in veterinary
and human medicine. These antibiotics are active on Gram-
positive bacteria and their mode of action relies on binding to the
bacterial ribosome at the level of the peptidyl transferase centre,
therefore inhibiting protein synthesis1. Pleuromutilin was ﬁrst
discovered by Kavanagh et al.2 from the two basidiomycete fungi
Pleurotus mutilis (synonymous to Clitopilus scyphoides f. mutilus)
and Pleurotus passeckerianus (synonymous to Clitopilus passeck-
erianus). It is now known to be also produced by a number of
other related species3 and its chemical structure and cyclisation
mechanism (Fig. 1a) were elucidated by independent work con-
ducted by Arigoni4, 5 and Birch et al.6. The semi-synthetic
pleuromutilin analogues tiamulin and valnemulin (Fig. 1a) have
been used for over three decades to treat economically important
infections in swine and poultry7–10 without showing any sig-
niﬁcant development of resistance in their target bacteria. Reta-
pamulin (Fig. 1a), another pleuromutilin derivative, was approved
in 2007 for the use in human medicine as a topical treatment for
impetigo and other skin infections, being also active on
methicillin-resistant Staphylococcus aureus (MRSA)11. In recent
years extensive research including structure–activity relationship
(SAR) studies have been conducted with the aim of generating
new orally available pleuromutilin derivatives to be used sys-
temically in human medicine to treat acute bacterial skin and skin
structure infections12, 13, as well as multidrug-resistant tubercu-
losis14, with more than a thousand compounds being
synthesised15.
Since an increasing number of semi-synthetic derivatives of
this diterpene antibiotic are being produced, understanding the
biosynthetic pathway to pleuromutilin is an essential requirement
for the effective and robust large-scale production of the natural
product for use as starting material in these synthetic endeavours.
The biosynthetic pathway to pleuromutilin has so far only been
inferred through limited feeding experiments of the producing
fungi with isotope-labelled predicted precursors16, 17, but a full
picture of the pathway and a genetic characterisation of the
enzymes involved in catalysis of each step of the biosynthesis are
still lacking.
Biosynthetic pathways of fungal secondary metabolites are
often characterised through generation of silenced or knockout
mutant strains, where downregulation of biosynthetic genes or
targeted-gene-deletion lead to accumulation of intermediates, as
recently shown by Lin et al.18 for the pathway of the commu-
nesins. Heterologous expression of the biosynthetic genes for a
secondary metabolite of interest in a ﬁlamentous fungus sec-
ondary host is also an established alternative for characterising
gene function, as reviewed by Lazarus et al.19 and Alberti et al.20.
Aspergilli and other physiologically well-characterised ﬁla-
mentous fungi are commonly employed for this purpose, as
effective engineering toolboxes are available for their transfor-
mation. Among these, Aspergillus oryzae is known to have a low
background in secondary metabolite production, despite having
the potential for producing the building blocks for all main fungal
secondary metabolites. A. oryzae has been successfully employed
to recreate partial or total biosynthesis of natural products from
other ascomycete fungi, such as the polyketide (PK) citrinin21, the
polyketide–non-ribosomal peptide (PK–NRP) hybrid tenellin22,
non-ribosomal peptide (NRP) siderophores such as ferrirhodin23,
the indole-diterpene paxilline24, the diterpene aphidicolin25 and
the meroterpenoid pyripyropene26.
The gene cluster for the antibiotic pleuromutilin (1) was
recently isolated in C. passeckerianus27. Total de novo biosynth-
esis of 1 was achieved through the expression of the entire gene
cluster in the secondary host A. oryzae, proving that the seven
genes isolated were sufﬁcient for biosynthesis of the diterpene
antibiotic. However, this still did not provide insights into the
function of each individual gene, nor on the nature of the
intermediate compounds produced along the pathway. We report
here genetic characterisation of the steps involved in the bio-
synthesis of 1, through a logical stepwise expression of genes from
the pleuromutilin gene cluster in A. oryzae, coupled with isolation
and detailed structural elucidation of the pathway intermediates
by spectroscopic methods and comparison with synthetic stan-
dards. This pathway engineering approach has given insights into
pleuromutilin biosynthesis and creation of a panel of A. oryzae
strains designed to accumulate each pathway intermediate as a
ﬁnal product. Furthermore, full elucidation of a biosynthetic
pathway of a basidiomycete natural product has been uncovered
using an ascomycete secondary host. We envisage our work will
pave the way for future characterisation of biosynthetic pathways
of other basidiomycete natural products in ascomycete hetero-
logous hosts, bypassing the need for genetic manipulation of
intractable basidiomycete species. Moreover, in industrial pro-
duction of antibiotics, replacing chemical synthesis steps with
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Fig. 1 Pleuromutilin commercial derivatives and proposed cyclisation mechanism. a Structure of pleuromutilin and its commercial derivatives. b Outline of
cyclisation to the pleuromutilin tricyclic scaffold, as reported by Arigoni4, 5 and Birch et al.6. The class II terpene synthase domain of Pl-Cyc promotes ring
contraction during the protonation-dependent cyclisation of GGPP. The class I terpene synthase domain then catalyses formation of the 8-membered ring
through ionisation-dependent dephosphorylation. Trapping with water introduces the ﬁrst hydroxy group of the molecule at C-14 of the tricyclic scaffold
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enzymatic biosynthesis represents an appealing and inexpensive
alternative, and is considered a way of reducing manufacturing
costs20. Here we show that our heterologous system can also be
employed as a chassis to generate semi-synthetic derivatives of
pleuromutilin, where a suitably engineered A. oryzae strain
accepts a chemically modiﬁed pleuromutilin intermediate and
takes the pathway to completion. This work led to generation of a
semi-synthetic derivative of 1, which exhibited enhanced anti-
biotic activity against Bacillus subtilis.
Results
Analysis of gene silencing for pathway elucidation. Silencing of
genes is a recognised molecular tool employed to study gene
function in fungi, as shown for example by Nakayashiki et al.28
for the ascomycete model Magnaporthe oryzae. Since silencing of
the genes of the pleuromutilin cluster was previously established
in C. passeckerianus29, we attempted detection of pleuromutilin
intermediates from the extracts of the silenced lines for the
pleuromutilin biosynthetic genes generated by Bailey et al.27.
However, whilst pleuromutilin production ceased in the trans-
formants, surprisingly no accumulation of pleuromutilin pre-
cursors could be detected from the crude extracts. RT-PCR from
RNA extracted under normal production conditions failed to
generate any products relating to pleuromutilin pathway genes—
even those genes that were not targeted in the silencing experi-
ment (Supplementary Fig. 1). This suggested that silencing of
individual genes from the cluster triggered the downregulation of
all the other genes known to be involved in biosynthesis of
pleuromutilin. Since gene silencing was not a suitable means to
achieve detailed functional characterisation of the genes of the
pleuromutilin cluster in C. passeckerianus, instead we set out to
undertake stepwise heterologous expression in the secondary host
A. oryzae to build the pathway.
A diterpene synthase creates 14-hydroxytricyclic terpene 2. In
order to heterologously express the genes of the pleuromutilin
cluster in A. oryzae, we generated expression vectors based on the
plasmids developed by Pahirulzaman et al.30. Because of the high
intron density in basidiomycete genes and possibilities of mis-
splicing from genomic clones, cDNA of these genes was used to
construct the expression cassettes (see Supplementary Methods
for details on vectors construction). Arigoni5 and Birch et al.6
showed that biosynthesis of pleuromutilin (1) proceeds via
cyclisation of geranylgeranyl diphosphate (GGPP) to generate a
C-14 carbocation, which is trapped with water to give 2 (Fig. 1b).
This proposed cyclisation mechanism has been supported by
isotopic labelling studies; for instance, Arigoni reported incor-
poration of label with [2-14C]-mevalonate at C-3, C-7, C-13 and
C-17 in pleuromutilin, fully consistent with the proposed cycli-
sation mechanism5. The gene cluster for 1 from C. passeckerianus
contains both a pathway-speciﬁc geranylgeranyl diphosphate
synthase (Pl-ggs) gene, expected to provide GGPP, and a cyclase
(or diterpene synthase, Pl-cyc) gene27. On the basis of homology
searches, the Pl-cyc was inferred to encode a bifunctional diter-
pene synthase, which catalyses the protonation-dependent cycli-
sation of GGPP—promoted by the class II terpene synthase
domain of the enzyme—as well as the ionisation-dependent
dephosphorylation reaction—catalysed by the class I terpene
synthase domain (Fig. 1b).
To investigate the ﬁrst step in biosynthesis of 1, the cDNA of
Pl-ggs—for putative increased production of GGPP—and Pl-cyc
genes from C. passeckerianus were co-expressed in A. oryzae
NSAR1, generating the transformant strain A. oryzae GC (see
Table 1 for full a list of the strains generated, and Supplementary
Methods for A. oryzae transformation and analysis of transfor-
mants). Reverse-phase HPLC failed to detect any new products in
A. oryzae GC in comparison to untransformed controls, however
a new compound was apparent by thin-layer chromatography
(TLC) (Supplementary Fig. 2). Preparative TLC was used to
purify the product, yielding 5 mg from 1 L of culture. The
chemical ionisation (CI) mass spectrum gave m/z [M +H]+
291.2688 (C20H35O) and the structure of 14-alcohol 2 was
elucidated by extensive NMR studies (see Supplementary Figs. 3,
5 and 7–10 for NMR spectra and Supplementary Table 1 for
NMR assignment and chemical ionisation mass spectrometry
(CIMS) data).
To conﬁrm the structure of alcohol 2 an authentic sample was
prepared from commercially available tiamulin (Fig. 2). Hydro-
lysis of tiamulin gave mutilin 5 which was protected as the 14-
monosilyl ether 8. The regiocontrol in the protection step was
conﬁrmed by conversion of alcohol 8 to acetate 9 which showed a
characteristic downﬁeld shift of the signal assigned to 11-H in the
1H-NMR spectrum. Following reduction of the 3-ketone to
alcohol 10, the 19,20-alkene was temporarily protected via
hydroboration and selective esteriﬁcation of the resultant primary
alcohol giving 12. The 3- and 11-hydroxy groups were removed
via radical reduction and then pivoyl ester 13 was reduced to
alcohol 14. Following dehydration then deprotection of the silyl
ether 15, the target alcohol 2 was isolated. The 1H- and 13C-NMR
spectra of the synthetic sample 2 (see Supplementary Figs. 4 and 6
for NMR spectra) were identical to those of alcohol 2 isolated
from extracts from A. oryzae GC, conﬁrming the structure of the
natural product.
Hence, we can conclude that heterologous expression in A.
oryzae of the Pl-ggs and Pl-cyc genes from the pleuromutilin gene
cluster gives alcohol 2 as the ﬁrst cyclic intermediate on the
biosynthetic pathway to pleuromutilin. A similar reaction is
observed also in the ﬁrst step of biosynthesis of aphidicolin, where
the aphidicolan-16β-ol synthase encoded by the PbACS gene
catalyses cyclisation of GGPP to give a tetracyclic product that
contains a hydroxyl function25. Like other fungal diterpene gene
clusters, such as that for aphidicolin in Phoma betae31, the gene
cluster for 1 contains a pathway-speciﬁc Pl-ggs gene27, pre-
sumably to provide increased levels of GGPP25, the 20-carbon
precursor of diterpenes that comes from isopentenyl diphosphate
and dimethylallyl diphosphate.
Table 1 List of Aspergillus oryzae strains generated
Aspergillus oryzae strain Heterologous genes from C. passeckerianus Compounds produced de novo Reference
GC Pl-ggs, Pl-cyc 2
GCP1 Pl-ggs, Pl-cyc, Pl-p450-1 3
GCP1P2 Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2 4 This work
GCP1P2S Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2, Pl-sdr 5
GCP1P2SA Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2, Pl-sdr, Pl-atf 6
NSAR1 7 Pl-ggs, Pl-cyc, Pl-p450-1, Pl-p450-2, Pl-sdr, Pl-atf, Pl-p450-3 1, 6 Bailey et al.27
The C. passeckerianus genes expressed heterologously in these strains are reported, as well as related compounds produced de novo
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Characterisation of later steps of pleuromutilin biosynthesis.
With a heterologous system established for the generation of the
ﬁrst tricyclic biosynthetic intermediate (2) encountered along the
pathway, we aimed to characterise further metabolites produced
along the pathway. The gene Pl-p450-1—coding for a putative
Cytochrome P450 monooxygenase27—was expressed hetero-
logously in the Pl-ggs+Pl-cyc strain A. oryzae GC, generating
strain GCP1. Analysis of extracts by both TLC and HPLC
revealed a new product (Supplementary Fig. 11), which was
puriﬁed yielding 10 mg from 1 L of culture of 11,14-diol 3. The
1H-NMR spectrum of 3 displayed characteristic methine signals
at δ 3.33 (d, J 6.4 Hz) and δ 4.34 (d, J 8.3, Hz) (see Fig. 3b and
Supplementary Fig. 12) which on comparison with the spectrum
of mutilin, the 11,14-dihydroxy-3-ketone 5, correlated well with
the signals assigned to 11-H and 14-H respectively. Hence the
structure was tentatively assigned as 11,14-diol 3, which was
conﬁrmed by further extensive NMR studies combined with MS
(see Fig. 4b and Supplementary Fig. 11 for HPLC–MS, Supple-
mentary Figs. 12–16 and Supplementary Table 2 for NMR
characterisation of 3).
Co-expression of Pl-p450-1 and Pl-p450-2 in the A. oryzae
strain that harboured Pl-ggs and Pl-cyc gave the transformant
strain GCP1P2. A product (18 mg from 1L of culture) that was
absent in strain GC was detected by HPLC and its structure
assigned as triol (4) by high-resolution mass spectrometry
(HRMS) combined with 1D and 2D NMR (see Fig. 4b and
Supplementary Fig. 17 for HPLC–MS and Supplementary Figs. 18,
20 and 22–24 and Supplementary Table 3 for NMR data and
Electrospray ionization (ESI)-HRMS). To conﬁrm the proposed
structure of triol 4, a synthetic sample was prepared by reduction
of mutilin 5 (see Fig. 2 and Supplementary Figs. 19 and 21 for
NMR spectra of synthetic 4), and the stereochemistry of the 3-
hydroxy group established by nOe via irradiation of the signal
assigned to 3-H (δ 4.54) leading to enhancements of the signals
assigned to 2α-H, 4-H and 15-H3 (Supplementary Figs. 25 and 26).
For the conversion of triol 4 to pleuromutilin, oxidation of the
3-hydroxy group is required and the product of the gene Pl-sdr,
predicted from bioinformatics analysis to be a short-chain
dehydrogenase/reductase27 was proposed to catalyse this trans-
formation. Hence an expression cassette for Pl-sdr along with Pl-
p450-1 and Pl-p450-2 was transformed into the A. oryzae GC
strain. Following puriﬁcation of the extract by HPLC–MS the
expected 3-ketone, mutilin (5) (15 mg from 1 L of culture) was
isolated and fully characterised by both spectroscopic methods
and comparison with an authentic sample prepared by semi-
synthesis (see Fig. 4a, 4b and Supplementary Fig. 27 for
HPLC–MS of 5, Supplementary Figs. 28, 30 and 32–34 and
Supplementary Table 4 for NMR and ESI-HRMS data of 5, and
Supplementary Figs. 29 and 31 for NMR spectra of synthetic
sample).
To complete the biosynthesis of pleuromutilin (1) acetylation
of the 14-alcohol to acetate 6, previously isolated from C.
passeckerianus32, followed by hydroxylation of the acetate is
required. The gene cluster for 1 includes a predicted acetyl
transferase (Pl-atf)27 and an additional P450 oxidoreductase (Pl-
p450-3). Thus an A. oryzae transformant expressing all genes
from the pleuromutilin cluster except Pl-p450-3 was generated,
called GCP1P2SA, and the expected 14-acetate 6 was isolated (6
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mg from 1 L of culture) and characterised (see Fig. 4b and
Supplementary Fig. 35 for HPLC–MS, and Supplementary
Figs. 36–40 and Supplementary Table 5 for NMR and ESI-
HRMS data). Furthermore, expression of all seven genes of the
cluster, including Pl-p450-3 gave pleuromutilin 1 as the ﬁnal
product of the pathway (Fig. 4a)27.
Generation of bioactive derivatives of 1 within A. oryzae. In
order to study the metabolism of pleuromutilin intermediates to
1, as well as to carry out bio-conversion of chemically modiﬁed
analogues into pleuromutilin derivatives, we further established
A. oryzae as a platform to carry out selected late steps in pleur-
omutilin biosynthesis. We validated our system by converting 5
into 1 upon culturing of strain AP3 (harbouring Pl-atf and Pl-
p450-3 from C. passeckerianus) in the presence of 5 (100 mg L−1)
(see Supplementary Figs. 41 and 42 for NMR spectra). Interest-
ingly, triol 4—accumulated in strain GCP1P2—has not been
detected previously in extracts of C. passeckerianus or other
pleuromutilin-producing fungi. Hence to gain evidence that 4 is
an intermediate in the biosynthesis of 1 a feeding study was
conducted in the non-pleuromutilin producing A. oryzae
SAP3 strain (expressing Pl-sdr, Pl-atf and Pl-p450-3 from C.
passeckerianus, involved in the ﬁnal three steps of the pathway).
SAP3 was cultured in the presence of 4 (100 mg L−1), which was
converted to both acetate 6 and pleuromutilin 1 (see Supple-
mentary Figs. 43–46 for NMR spectra) in accord with triol 4
being an intermediate in pleuromutilin biosynthesis.
Once we established a system for conversion of pleuromutilin
intermediates into pleuromutilin within A. oryzae, we further
investigated the capability of this chassis to generate semi-
synthetic analogues of 1 upon feeding with chemically modiﬁed
analogues of the naturally occurring intermediates. In order to do
so, we ﬁrst prepared enone 18 starting from tiamulin (see
Supplementary Fig. 47 for chemical synthesis leading to 18). We
then cultured A. oryzae strain AP3 (containing Pl-atf and Pl-p-
450-3 genes from C. passeckerianus) in the presence of 18 (30 mg
in 300mL culture broth), and conﬁrmed the conversion of the
enone into its ester 20 (18 mg, 51%) and hydroxy ester 21 (8 mg,
23%) (see Fig. 5a for a scheme of the bio-conversion, and
Supplementary Figs. 48–51 for NMR spectra of the puriﬁed
products). We thus investigated the antimicrobial activity of these
two semi-synthetic derivatives against B. subtilis via plate-based
bioassay (see Supplementary Methods for details on the
antimicrobial bioassay procedure). The ester 20 produced an
inhibition zone on the growth of B. subtilis of 12.7± 0.6 mm (see
Fig. 5b and Supplementary Table 6), comparable to that of
pleuromutilin 1 (12.8± 0.8 mm) and higher than that of 6 (10.3
± 0.3 mm). Remarkably, the hydroxy ester 21 generated an
inhibition zone on the growth of B. subtilis of 15.7± 1.8 mm,
which was greater than that of both naturally occurring 1 and 6,
as well as of that of its precursor 18 (8.0± 0.0 mm). Each
antimicrobial bioassay was carried out in triplicate.
Discussion
Antimicrobial substances produced by microorganisms are a
valuable resource for the development of semi-synthetic anti-
biotics. The diterpene antibiotic pleuromutilin has provided leads
for the only commercial antibiotic produced from a basidiomy-
cete fungus, speciﬁcally from C. passeckerianus and other related
species3, and has led to the generation of semi-synthetic deriva-
tives7, 8, 10 for human and veterinary use. The ongoing efforts
towards the development of pleuromutilin analogues to be used
systemically in human medicine suggests that this class of anti-
biotics is yet to be exploited to its full potential12–14.
In this study, we have shown genetic characterisation of all the
steps involved in pleuromutilin biosynthesis from GGPP by
rational heterologous expression in A. oryzae coupled with iso-
lation and detailed structural elucidation of the pathway inter-
mediates by spectroscopic methods and comparison with
synthetic standards, as well as feeding puriﬁed intermediates into
suitably engineered host strains. A ﬁrst attempt to characterise
the biosynthesis of pleuromutilin (1) via gene silencing in the
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native producer C. passeckerianus failed to return any accumu-
lation of precursors. Transcript titres assessed by RT-PCR showed
this was due to the downregulation of all genes of the cluster
upon silencing of individual genes. This was unexpected,
although a similar occurrence has been reported in other fungal
secondary metabolite pathways33. As an alternative approach to
characterise the biosynthetic pathway, and with the knowledge
that full pleuromutilin production could be supported in A.
oryzae27, we adopted stepwise heterologous expression of the
genes of the cluster for 1. Similar strategies have been successfully
employed to characterise other fungal secondary metabolite
pathways21–26. This allowed us to show accumulation of each of
the ﬁve intermediates progressing to biosynthesis of 1 (Fig. 4),
including 3R,11S,14R-triol (4), showing that the C-3 keto is
derived in a two-step reaction via a hydroxy intermediate
requiring both Pl-p450-2 and Pl-sdr.
Heterologous expression in A. oryzae of the Pl-ggs and Pl-cyc
genes from the pleuromutilin cluster provided convincing evi-
dence that 14-alcohol 2 is the ﬁrst tricyclic intermediate generated
on the pathway, as previously proposed by Arigoni4. The cyto-
chrome P450 oxidoreductases encoded by Pl-p450-1 and Pl-p-
450-2 catalyse stereospeciﬁc hydroxylation of C-11 and C-3
respectively, and co-expression of Pl-ggs, Pl-cyc, Pl-p450-1 and Pl-
p-450-2 in A. oryzae gave accumulation of the putative inter-
mediate 4. Rather than being a shunt product, triol 4 was shown
to be a precursor of 1, through a feeding experiment of an A.
oryzae strain harbouring Pl-sdr, Pl-atf and Pl-p450-3, successfully
yielding pleuromutilin. Isolation of mutilin (5) in A. oryzae
GCP1P2S (Fig. 4) showed that 4 is further oxidised along the
pathway by the product of the gene Pl-sdr, indicating that Pl-sdr
is a short-chain dehydrogenase/reductase class of enzyme that
catalyses regiospeciﬁc oxidation of the 3-hydroxy group to a
ketone. The ﬁnal intermediate in the biosynthesis of 1 was pro-
duced de novo in A. oryzae by adding the Pl-atf gene (encoding
an acetyl transferase) to the heterologous system that was pro-
ducing 5, achieving sole production of 14-acetate 6 in GCP1P2SA
(Fig. 4). By inference this shows that Cytochrome Pl-p450-3 is
responsible for hydroxylation of acetate 6 to pleuromutilin, as
production of 1 was observed before27 when expressing all the
seven genes of the pleuromutilin gene cluster in A. oryzae,
including Pl-p450-3, which was lacking in A. oryzae GCP1P2SA
yielding 6.
The re-creation of a linear biosynthetic pathway to 1 by step-
wise gene addition, allowed us to prove the function of the genes
of the cluster from C. passeckerianus, and showed that bio-
synthesis of a basidiomycete secondary metabolite and its
intermediates can be studied in an ascomycete heterologous host.
Furthermore, we report here a full conversion of each inter-
mediate of the pathway to the next, with no bottleneck observed
in any of the biosynthetic steps (Fig. 4b), showing that our system
can allow for accumulation of each biosynthetic precursor in
amounts sufﬁcient for consequent puriﬁcation and full char-
acterisation. We envisage this approach could be employed in the
future to characterise the biosynthesis of other basidiomycete
secondary metabolites of pharmaceutical or agrochemical
relevance.
In this study, we also showed that the heterologous platform
recreated in the A. oryzae host can be employed to convert not
only pleuromutilin intermediates into 1, but also chemically
modiﬁed analogues into semi-synthetic derivatives, providing a
robust and ﬂexible chassis for semi-synthetic derivatisation of
pleuromutilin. Using this system, the chemically modiﬁed enone
18 was successfully bio-converted into ester 20 and hydroxy ester
21 (Fig. 5), with the latter showing increased antibiotic activity
over pleuromutilin against B. subtilis.
In current commercial production of pleuromutilin derivatives
the C-14 side chain of the naturally occurring antibiotic is
removed, then replaced with the synthetic side chain. Deploy-
ment of the A. oryzae transformant strain that accumulates
mutilin 5 could ﬁnd application in industrial production of
commercial pleuromutilins. Furthermore, the observation that a
suitably engineered A. oryzae strain can successfully take to
completion the pathway when fed with chemically modiﬁed
analogues of pleuromutilin intermediates, opens new avenues for
obtaining useful semi-synthetic derivatives of this antibiotic,
exploiting more fully the power of combining synthetic chemistry
and synthetic biology.
Methods
Reagents and conditions for growth of microorganisms. All chemicals were
purchased from either Sigma-Aldrich or Fisher Scientiﬁc, unless otherwise speci-
ﬁed, and were of analytical grade. Ingredients for media were purchased from
Oxoid or Formedium, unless otherwise speciﬁed. All media, solutions, glassware
and plastic-ware were sterilised by autoclaving at 121 °C for 15 min before use. C.
passeckerianus ATCC 34646, producer of pleuromutilin, was maintained on PDA
plates (24 g L−1 potato dextrose broth, 15 g L−1 agar) at 25 °C. A. oryzae NSAR1
(genotype niaD−, sC−, ΔargB, adeA−)34, used as heterologous host, was maintained
on MEA plates with appropriate supplements (15 g L−1 malt extract, 1.5 g L−1
arginine, 1.5 g L−1 methionine, 0.1 g L−1 adenine, 2 g L−1 ammonium sulphate, 15 g
L−1 agar) at 28 °C. Saccharomyces cerevisiae BY4742 (genotype MATα, his3Δ1,
leu2Δ0, lys2Δ0, ura3Δ0)35, used for homologous recombination-based construc-
tion of plasmids, was maintained on YPAD plates (10 g L−1 yeast extract, 20 g L−1
bactopeptone, 20 g L−1 D-glucose, 40 mg L−1 adenine hemisulfate, 15 g L−1 agar).
Escherichia coli One Shot ccdB Survival 2 T1 competent cells (Life Technologies)
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were used for propagation of plasmids by standard procedures. LB agar plates (10 g
L−1 NaCl, 10 g L−1 tryptone, 5 g L−1 yeast extract, pH 7) were used for growing E.
coli at 37 °C.
Genetic engineering of fungal strains. Silenced lines of C. passeckerianus used in
this study where those described in Bailey et al.27, where the antisense sequence of
each gene of the pleuromutilin cluster was placed under control of the Agaricus
bisporus gpdII promoter and expressed in C. passeckerianus. Expression vectors for
A. oryzae to contain the genes of the pleuromutilin cluster were constructed
through homologous recombination in yeast following the procedure described by
Ma et al.36. The seven genes of the pleuromutilin gene cluster—Pl-ggs, Pl-cyc, Pl-
p450-1, Pl-p450-2, Pl-p450-3, Pl-atf and Pl-sdr—were ampliﬁed using high-ﬁdelity
PCR from the cDNA of C. passeckerianus and cloned in pJET 1.2 cloning vectors
(see Supplementary Methods for details on cloning of the genes of the pleur-
omutilin cluster). Plasmids pTYGSarg, pTYGSade and pTYGSbar30 were used as
backbones to construct expression vectors with the intron-free genes of the
pleuromutilin cluster (plasmid maps and details of construction of expression
vectors are in Supplementary Methods), which were used to transform A. oryzae
NSAR1 and derived transformant strains. Protoplast-mediated transformation of
A. oryzae was carried out following an adapted protocol from the one described by
Halo et al.37. Details on the A. oryzae transformation procedure are reported in
Supplementary Methods. The vector pTYGSargGGSCyc (which included Pl-ggs
and Pl-cyc) was used for transformation of A. oryzae NSAR1, generating strain GC
(producer of 2). Further transformation of GC with pTYGSadeP1 (containing Pl-
p450-1) achieved production of strains GCP1 (producer of 3). Likewise, transfor-
mation of GC with pTYGSadeP1P2 (containing Pl-p450-1 and Pl-p450-2) returned
strains GCP1P2 (producer of 4). A combination of pTYGSadeP1P2 and pTYGS-
barSDR (containing Pl-sdr) was introduced into GC to produce strain GCP1P2S
(producer of 5), whereas a combination of pTYGSadeP1P2 and pTYGSbar-
ATFSDR (containing Pl-atf and Pl-sdr) was used to transform strain GC to achieve
GCP1P2SA (producer of 6). Strain AP3, used for feeding experiment with 5, was
generated by transforming A. oryzae NSAR1 with a combination of pTYGSadeP3
(containing Pl-p450-3) and pTYGSbarATF (containing Pl-atf), whereas strain
SAP3 used for feeding experiment with 4 was obtained by transforming A. oryzae
NSAR1 with a combination of pTYGSadeP3 (containing Pl-p450-3) and pTYGS-
barATFSDR (containing Pl-atf and Pl-sdr).
Synthetic chemistry. Selected proposed biosynthetic intermediates were synthe-
sised as presented in Fig. 2 and described in the main text, in order to conﬁrm by
NMR the structure of the compounds produced de novo in engineered fungal
strains, as well as to give standards for HPLC–MS. Enone 18 was synthesised as
presented in Supplementary Fig. 47.
Chemical analysis on A. oryzae transformants. A. oryzae transformants were
analysed for production of metabolites. Each transformant strain was grown in 100
mL of CMP medium (35 g L−1 Czapek-dox liquid, 20 g L−1 maltose, 10 g L−1
peptone) at 28 °C for 10 days prior to proceeding with organic extractions with
ethyl acetate, concentrating the crude extract in vacuo and dissolving in methanol.
For the A. oryzae strains GC, AP3 (fed with 5) and SAP3 (fed with 4), the crude
extracts were analysed for detection of metabolites by using TLC. Fungal crude
extracts were transferred to 20 × 20 cm TLC plates (TLC silica gel 60 F254; Merck,
Darmstadt, Germany), which were developed in petroleum spirit-ethyl acetate (9:1
for strain GC, 1:1 for strains AP3 and SAP3). This led to 5 mg of 2 from the crude
extract of strain GC, 6 mg of 1 from the extract of AP3 (fed with 5), 4 mg of 1 and
3 mg of 6 from the extract of SAP3 (fed with 4). For the puriﬁcation of the crude
extract of AP3 fed with the synthetic analogue 18 (30 mg in 300 mL broth) ﬂash
column chromatography was employed, using a silica gel with pore size 60 Å and
particle size 40–60 µm (Sigma Aldrich). Fractions were collected in glass tubes,
pooled in a pre-weighed glass vial and concentrated in vacuo. Using this procedure,
puriﬁcation of 18 mg of acetate 20 and 8 mg of hydroxy acetate 21 was achieved.
For all other strains the crude extracts were analysed with analytical HPLC–MS by
using a Waters 2767 HPLC system with a Waters 2545 pump system, and a
Phenomenex LUNA column (2.6 μ, C18, 100 Å, 4.6 × 100 mm) equipped with a
Phenomenex Security Guard precolumn (Luna C5 300 Å). A reverse-phase HPLC
with a gradient of solvents was used (A, HPLC grade H2O containing 0.05% formic
acid; B, HPLC grade CH3CN containing 0.045% formic acid) with the following
programme: 0 min, 10% B; 15 min, 90% B; 16 min 95% B; 17 min 95% B; 18 min
10% B, 20 min 10% B. Flow rate was set at 1 mLmin−1. Preparative HPLC–MS was
used to purify compounds from the crude extract of A. oryzae transformants that
were absent in the A. oryzae control strain. For this purpose a 1-L culture of the
chosen fungal strain was set up and extracted with the same conditions described
when undertaking analytical HPLC–MS. Fractions that contained target com-
pounds were puriﬁed using reverse-phase HPLC on a Waters mass-directed
autopuriﬁcation system with a Waters 2767 autosampler and Waters 2545 pump
system, a Phenomenex LUNA column (5μ, C18, 100 Å, 10 × 250 mm) for reverse-
phase chromatography, equipped with a Phenomenex Security Guard precolumn
(Luna C5 300 Å), eluted at 16 mLmin−1. A gradient of solvents was used (A, HPLC
grade H2O containing 0.05% formic acid; B, HPLC grade CH3CN containing
0.045% formic acid) with the following programme: 0 min, 5% B; 2 min, 10% B;
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20 min, 90% B; 21 min 95% B; 26 min 95% B; 27 min 5% B, 30 min 5% B. Speciﬁc
fractions were collected in glass tubes, pooled in a pre-weighed glass vial and
concentrated in vacuo. Using this
procedure, puriﬁcation of 10 mg of 3, 18 mg of 4, 15 mg of 5 and 6 mg of 6
was achieved. Details of the procedures used for ethyl acetate organic extractions,
TLC, analytical and preparative HPLC–MS are also reported in Supplementary
Methods.
Spectroscopic analyses of puriﬁed metabolites. The metabolites puriﬁed from
A. oryzae transformants were characterised by NMR spectroscopy. The samples
were dissolved in CDCl3 or CD3OD and spectra were obtained with an Agilent
VNMRS500 spectrometer (1H 500MHz, 13C 125MHz). Chemical shifts were
recorded in parts per million (ppm) and coupling constant (J) in Hz. Chemical
shifts for 1H-NMR are reported relative to the proton resonance δ 7.26 of CHCL3
or δ 4.78 of CH3OH, whereas shifts for 13C-NMR are reported relative to the
carbon resonance δ 77.16 of CDCl3. ESI-HRMS was performed with a
Bruker Daltonics microTOF focus using positive ESI. Chemical ionisation mass
spectrometry was performed with a VG/Micromass Autospec operated in positive
mode. NMR spectra and ESI-HRMS/CIMS data for the metabolites produced
de novo from the A. oryzae engineered strains are reported in Supplementary
Information.
Bio-conversion of precursors into 1 and derivatives. Liquid cultures of AP3 and
SAP3 were set up in 100 mL of CMP medium with the addition of 4 and 5 (100 mg
L−1) respectively, and grown for 10 days at 28 °C prior to proceeding with organic
extractions with ethyl acetate and concentration of the crude extracts in vacuo.
TLC was used to purify 1 from the crude extract of strain AP3 (fed with 5), as well
as 1 and 6 from the crude extract of strain SAP3 (fed with 4), and the structures
conﬁrmed by 1H-NMR and 13C-NMR. For bio-conversion of 18, liquid cultures of
AP3 were set up in 100 mL of CMP medium with the addition of 18 (100 mg L−1).
Organic extractions with ethyl acetate and concentration of the crude extract
in vacuo were followed by column chromatography (10–20% EtOAc in petrol) for
puriﬁcation of 20 (23 mg, 67%) and 21 (14 mg, 39%). 1H-NMR and 13C-NMR
were carried out to conﬁrm the structures.
Data availability. All data is available from the authors upon reasonable request.
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